Black patients have a twofold increased risk of induction mortality compared to White patients with acute myeloid leukemia (AML). We reviewed diagnosis and billing data from Pediatric Health Information System for 28 AML Induction I deaths to investigate conditions preceding death in White and Black patients. Half of deaths occurred within 10 days of initial diagnostic admission. Respiratory, cardiac, renal, and infectious complications were common prior to both White and Black deaths. Deaths in White patients were more commonly preceded by intracranial hemorrhage compared to deaths in Black patients. Future studies should assess management approaches of complications by race to identify modifiable processes that reduce mortality.
INTRODUCTION
In the last four Children's Oncology Group studies, Black children with acute myeloid leukemia (AML) had lower overall survival than White children with the most recent study showing a twofold increased risk of death in Black children. [1] [2] [3] Early death, defined as occurring within 42 days of diagnosis, accounts for more than 10% of mortality in pediatric patients with AML. 4 Early deaths have previously been associated with low performance status, French-American-British type M4 and M5, hyperleukocytosis, 5, 6 thrombocytopenia, 7 and older age. 4, 8 We recently demonstrated that induction mortality among Black children with AML was more than twice that of White children. 9 This disparity was associated with increased frequency of multiorgan system 
METHODS
We present a case series of patients with newly diagnosed AML between January 2004 through June 2014 who died during Induction I. These deaths were identified from an AML cohort in the Pediatric Health Information System (PHIS) database assembled by a previously validated process. 11 The source cohort excluded patients who did not TA B L E 1 Occurrence of specific diagnoses (n, %) and resource utilization among patients with AML who died during induction, overall and by race Table S1 ).
Median time to death was compared using the log rank test. For each patient, all recorded ICD-9 diagnosis codes were grouped according to specific systems (e.g., cardiac, respiratory, renal) and billing data and ICD-9 procedure codes were used to assess ICU-level resources utilized (e.g., vasopressors, dialysis). The frequency (%) of system-based complications and resource requirements were compared between Black and White patients who died using the chi-square test (Table 1) .
RESULTS
There were 28 deaths (9 Black and 19 White) identified during Induc- (Fig. 1) . Demographic characteristics were similar between Black and White patients who died with the exception of age: Black patients who died were older at the time of diagnosis (P < 0.006, Supplementary Table S2 ).
Specific details regarding preexisting conditions and complications sustained by each patient prior to death are shown in Table S1 . Cardiac, renal, respiratory, neurologic, and infectious complications were present in greater than 50% of both White and Black deaths with no detectable differences between the two groups ( Table 1) . There were higher rates of intracranial hemorrhage, based on ICD-9 codes, among White patients compared with Black patients who died during (Table 1) .
DISCUSSION
This report describes complications observed in a series of Black and White patients' deaths during Induction I among a cohort of children with newly diagnosed AML. In light of our previous finding of increased induction mortality among Black children, 9 we sought to further explore similarities and differences in clinical course between Black and White patients who died. Overall, more than half of deaths occurred within a week of chemotherapy initiation and deaths were often preceded by respiratory, cardiac, renal, and infectious complications as well as the need for intensive care resources (such as vasopressors and mechanical ventilation). Interestingly, there were no significant differences between Black and White patients' deaths with regard to time to death or utilization of intensive care resources.
Black patients tended to be older at the time of death. The difference in age distribution observed among those patients who died is consistent with our previous finding that age is a confounder in the association between race and mortality. 9 Importantly, a number of the White patients who died had congenital heart disease or prematurity, while the profile of preexisting conditions for Black patients who died included asthma and autism (Table S1 ). The two most common causes of death in AML are hemorrhage and infection. 6 We observed intracranial hemorrhage more frequently among White children who Moreover, the severity of infection could not be discerned from the available administrative data. These factors may have obscured detection of infection-related mortality.
There are well-documented issues with sensitivity and specificity of ICD-9 codes. [12] [13] [14] In addition, diagnosis codes do not provide insight into temporal relationships between diagnoses. However, the use of resource utilization information in combination with diagnoses codes sheds some light on temporal associations. PHIS data do not contain laboratory or imaging results or specific information about cause of death so the actual events leading to each patient's death can only be inferred; however, cause of death is difficult to discern even in traditional chart reviews. 15 In addition, while this series is among the largest descriptions of pediatric AML induction mortality, our power to detect statistically significant differences between the Black and White populations is limited by how rarely early deaths occur.
While we did not identify factors, other than age-related comorbidities and intracranial bleeding, which varied between Black and White patients' deaths, our approach of using administrative data to examine individual patients' clinical trajectory is unique and highlights the richness of the information contained in the PHIS database (Table   S1 ). Understanding the detailed clinical experience of patients who died during Induction I AML therapy provides direction to compare how complications that frequently precede death, such as infectious, cardiac, neurologic, renal, and respiratory complications, are managed when they are present during the course of therapy in White and Black patients.
